Supplements

Prevalence estimates for gastroesophageal reflux disease (GERD) range from 8% to 40%, depending on the definition and diagnostic criteria.^1-4 While heartburn and regurgitation are considered the hallmark symptoms, GERD actually represents a spectrum of disorders that generally result from transient relaxations of the lower esophageal sphincter (LES), so that gastric refluxate comes into contact with the esophageal epithelium. Additionally, differences in rates of acid secretion and clearance and the time since food ingestion affect symptoms, potentially leading to differing presentations of GERD associated with daytime and nocturnal episodes. To facilitate accurate diagnosis of GERD, it may be helpful for clinicians to distinguish between the symptoms that occur during the day or in an upright position and those that occur at night or when a person is supine.⁴ This paper reviews the differences in symptoms and explains the pathophysiologic mechanisms involved.

Issues of GERD and quality of life

Patients’ quality of life and ability to function is negatively impacted by factors associated specifically with nocturnal episodes of GERD. Patients who experience GERD primarily at night may complain of sleep disturbances. Symptoms associated with nighttime GERD generally are more severe,⁵ and the complications more diverse and frequent,⁴ due to the prolonged length of nighttime reflux.⁶ For these reasons, determining if the underlying cause of a group of symptoms is nighttime episodes of GERD is an important treatment step.

Complications of reflux: associations with nighttime occurrences

Esophageal complications of GERD include erosive esophagitis, esophageal hemorrhage, ulceration, and strictures and appear to be more severe in patients with nighttime episodes of GERD than in those complaining of daytime reflux. An early study showed that patients who experience reflux only in the supine position have a higher incidence of esophagitis compared with patients who only refluxed in an upright position.⁷ Prolonged acid contact time increases the risk that esophagitis will become erosive. This was demonstrated in a study that concluded particularly that the presence of nocturnal reflux events lasting more than 5 minutes was a powerful predictor of erosive damage.⁶

Overall, approximately 7% to 12% of patients with chronic GERD develop Barrett’s esophagus compared with fewer than 1% of those in the general population.⁸ Potentially, more severe nocturnal symptoms may be among the factors that increase the risk of Barrett’s esophagus.^9,10 Esophageal adenocarcinoma also is more likely in patients with nocturnal episodes of GERD: In a national, population-based, case-controlled trial, an 11-fold increased risk for esophageal adenocarcinoma was reported in patients who experienced once-weekly episodes of nighttime heartburn, regurgitation, or both. Overall, an 8-fold increased risk of esophageal adenocarcinoma was observed in all patients with GERD.¹¹

Impact of nighttime episodes on sleep

Not surprisingly, sleep is significantly affected by nighttime GERD episodes. A recent Internet-based survey of full-time working adults in the United States identified 1002 patients with symptomatic GERD.¹² Using the validated GERD Symptom and Medication Questionnaire, symptomatic GERD was defined as a score of 10 or greater for at least one episode of heartburn or acid regurgitation within the past 7 days. Symptomatic nighttime GERD was defined as at least 2 nights with symptoms during the past 7 days. GERD-related sleep problems were twice as frequent in patients with nighttime compared with daytime GERD. Patients with nighttime episodes of GERD experienced GERD-related sleep impairment an average of 1.6 to 1.9 nights per week compared with 0.3 to 0.4 nights per week for the daytime GERD group.

In both groups, the most commonly reported sleep problem was awakening due to symptoms (75% vs 37%, respectively). Sixty-five percent of nighttime and 28% of daytime GERD patients indicated that GERD symptoms prevented them from feeling rested in the morning.¹² In addition, respondents with nighttime GERD experienced an additional 2.7 hours per week of lost work productivity when compared to those with daytime GERD.¹³ A similar survey also found that in those with nighttime GERD, the number of nights with sleep interference was associated with reduced work productivity.¹⁴

These results are consistent with 2 previous telephone surveys. In one survey, 13% of 1000 adults who experienced heartburn at least weekly had only nighttime episodes; 20% reported only daytime heartburn.¹⁵ Altogether, 79% of the heartburn sufferers reported experiencing heartburn at night. Of these, 75% reported that heartburn had a negative impact on sleep; 63% indicated that heartburn adversely affected their ability to sleep well; and 40% reported impaired functioning the next day. The prevalence of sleep disturbances increased directly with the incidence of nighttime heartburn.

The second telephone survey of persons with nighttime GERD had lower scores using the Short-Form 36 Health Survey (a measure of quality of life) than did persons with daytime GERD or controls (TABLE 1).⁴ In another study, the greatest differences between groups occurred in terms of physical and emotional role functioning, vitality, and general health.¹⁶ A comparison with other major disorders affirmed the substantial impairment in health-related quality of life caused by nighttime GERD (TABLE 2).⁴

In summary, although heartburn and regurgitation are common in daytime and nighttime GERD, patients with nighttime GERD are more likely to experience impaired sleep, fatigue, reduced work productivity, and decreased quality of life.

TABLE 1
Adjusted medical outcomes study Short-Form 36 Health Survey scores

TABLE 2
Mean medical outcomes study Short-Form 36 Health Survey scores

Diagnosis: evaluation of symptoms

Physicians should inquire specifically about GERD symptoms to ensure diagnosis, as the signs of GERD are often subtle, nonspecific, or judged to be trivial by patients. Symptoms of GERD may include esophageal or nonesophageal complaints, or both. Importantly, heartburn or regurgitation may be absent in many patients: One group of investigators reported that neither heartburn nor regurgitation was experienced by approximately half of all patients who had nonclassical symptoms of GERD.³

Nonesophageal symptoms associated with GERD

Laryngitis, laryngospasm, chronic cough, hoarseness, excessive throat clearing, and globus pharyngeus are common nonesophageal symptoms in patients with GERD (TABLE 3).^17,18 In a recent investigation, 86% and 77% of patients with nighttime and daytime episodes of GERD, respectively, reported one or more nonesophageal symptom. In patients experiencing GERD at night, the most common symptoms were sinusitis (52%), dry cough/throat clearing (49%), and snoring (47%). Symptom severity scores were significantly higher in the nighttime vs daytime GERD groups (2.42 vs 1.80, respectively).⁵

In a cross-sectional international population survey of 2202 randomly selected persons and 459 additional individuals with asthma, Gislason et al estimated the possible association between reported symptoms of nighttime GERD, sleep-disordered breathing, respiratory symptoms, and asthma. The investigators reported a 2- to 3-fold increased prevalence of asthma and other respiratory symptoms (such as wheezing, chest tightness, breathlessness, and nighttime cough) in patients with nighttime reflux.¹⁹

TABLE 3
Nonesophageal conditions associated with GERD

Patient history

The patient’s history is the primary focus of the diagnostic workup and the physician should explore patient risk factors for GERD. For patients with atypical symptoms of GERD, the history is especially important to determine the diagnosis.

The presence of at least one esophageal or non-esophageal sign and symptom should prompt consideration of GERD as the cause, and discussion with the patient may help classify GERD further. The symptoms of nighttime GERD range from mild to severe. Though they can be similar to the symptoms of daytime GERD, nocturnal symptoms may be exacerbated by lying down or may differ in their manifestation. Asking questions about a patient’s quality of sleep, with input from the patient’s sleep partner, if possible, is useful in assessing nighttime GERD (TABLE 4).

TABLE 4
Key questions in the assessment of nighttime GERD

Predictors of nighttime reflux

A high body mass index (BMI) may lead to a reduction in LES pressure and is a risk factor for GERD.^20,21 Social habits such as smoking and alcohol use are often cited as risk factors for GERD; however, data to confirm this premise are lacking.¹¹ Several other factors and the presence of some pulmonary disorders may be specific predictors and indications of nighttime GERD episodes.

A recent large prospective cohort study specifically evaluated predictors of heartburn during sleep. Symptoms of GERD were strongly associated with increased BMI, carbonated soft drink consumption (possibly due to low pH), snoring and daytime sleepiness, insomnia, hypertension, asthma, and usage of benzodiazepines (TABLE 5).²⁰ It was noted that the association of hypertension with nighttime heartburn likely is a reflection of factors associated with hypertension rather than hypertension itself. Possible factors of hypertension include antihypertensive medications, comorbidities, diet, and body habitus.²⁰

Several sleep-related and respiratory factors are associated with nighttime GERD. Among these, insomnia and sleepiness are probably consequences rather than causes of nighttime reflux. An association of GERD with obstructive sleep apnea has been established, although causality has not been determined. Similarly, asthma is clearly associated with GERD, but the extent of causality remains unclear. Nonetheless, nighttime GERD should be suspected in patients who present with one of these sleep disturbances, particularly obstructive sleep apnea, or adult-onset or difficult-to-treat asthma.²⁰

TABLE 5
Factors associated with nighttime GERD

Diagnostic tests for GERD

Various tests have been investigated for the diagnosis of all types of GERD, and there is no difference in the tests used when nighttime GERD is suspected. Endoscopy is an important diagnostic tool for either identifying or ruling out complications such as erosions or Barrett’s esophagus. Esophageal pH monitoring can be helpful in diagnosis.

Pathophysiology: potential differences between daytime and nighttime GERD

Several mechanisms have been established to contribute to the development of GERD. Included are transient LES relaxations and, less frequently, sustained LES pressure abnormalities. Other factors that contribute to the pathophysiology of GERD include hiatal hernia, which reduces LES pressure and impairs acid clearance, and poor esophageal clearance.²²

Despite their similarities, important pathophysiologic differences between daytime and nighttime gastroesophageal reflux can be seen. Increased acid secretion and gastric volume are associated with food consumption, so daytime reflux and associated symptoms tend to occur after meals. Nighttime gastroesophageal reflux occurs less frequently, but the episodes are of longer duration than those of daytime reflux, as a result of delayed acid clearance from the esophagus at night.^6,7,23

Sleep-related mechanisms combined with impairment of the LES and the supine position help explain the more common and severe symptoms and wider range of complications seen in nighttime compared with daytime GERD.

Protective processes impaired during sleep

Differences between daytime and nighttime GERD are thought to be due to the sleep state rather than just to differences in posture (TABLE 6).^24,25 Processes that occur normally during the day to facilitate refluxed acid clearance from the esophagus, such as swallowing and acid neutralization (via bicarbonate-containing salivation), are suppressed during sleep.²⁵

Saliva, composed of mucus, bicarbonate, and epidermal growth factor, neutralizes refluxed acid and protects esophageal tissue. Saliva production is diminished during sleep, with implications for GERD symptoms.^26,27 Swallowing is reduced during sleep and may not occur during deeper stages of sleep.²⁸ Absence of the voluntary swallow-initiated peristaltic wave of esophageal contractions during sleep also results in reduced volume clearance.²⁹

Delayed gastric emptying during sleep may result in increased gastric distention and contribute to the occurrence of nighttime reflux.^25,30

TABLE 6
Sleep-related mechanisms contributing to nighttime GERD

Effect of reduced consciousness

Reflux during sleep may be accompanied by a brief period of arousal, which helps to hasten esophageal clearance of refluxate and protect the airway against aspiration and acid exposure.²⁵ However, arousal does not occur in all reflux episodes, since the conscious perception of heartburn is absent during sleep. Consequently, the sleep-induced mechanisms are allowed to persist leading to prolonged periods of acid exposure.²⁵

Summary

For the purposes of understanding symptoms and facilitating diagnosis, GERD can be divided into daytime and nighttime GERD. Compared with daytime GERD, nighttime reflux episodes occur less frequently but are more prolonged. In addition, nighttime symptoms are more common and more severe, and esophageal and nonesophageal complications are more likely. The presence of severe symptoms or at least one esophageal and/or nonesophageal symptom should prompt an investigation of nighttime GERD. In doing so, the history and physical examination findings are the most helpful; laboratory values and other test results are generally less so. Physiologic alterations during sleep are thought to be the primary factors that contribute to nighttime symptoms.

EDITOR’S NOTE:
This article is meant to alert the reader to different symptomatology in GERD at night; therefore, treatment will not be discussed.

Prevalence estimates for gastroesophageal reflux disease (GERD) range from 8% to 40%, depending on the definition and diagnostic criteria.^1-4 While heartburn and regurgitation are considered the hallmark symptoms, GERD actually represents a spectrum of disorders that generally result from transient relaxations of the lower esophageal sphincter (LES), so that gastric refluxate comes into contact with the esophageal epithelium. Additionally, differences in rates of acid secretion and clearance and the time since food ingestion affect symptoms, potentially leading to differing presentations of GERD associated with daytime and nocturnal episodes. To facilitate accurate diagnosis of GERD, it may be helpful for clinicians to distinguish between the symptoms that occur during the day or in an upright position and those that occur at night or when a person is supine.⁴ This paper reviews the differences in symptoms and explains the pathophysiologic mechanisms involved.

Issues of GERD and quality of life

Patients’ quality of life and ability to function is negatively impacted by factors associated specifically with nocturnal episodes of GERD. Patients who experience GERD primarily at night may complain of sleep disturbances. Symptoms associated with nighttime GERD generally are more severe,⁵ and the complications more diverse and frequent,⁴ due to the prolonged length of nighttime reflux.⁶ For these reasons, determining if the underlying cause of a group of symptoms is nighttime episodes of GERD is an important treatment step.

Complications of reflux: associations with nighttime occurrences

Esophageal complications of GERD include erosive esophagitis, esophageal hemorrhage, ulceration, and strictures and appear to be more severe in patients with nighttime episodes of GERD than in those complaining of daytime reflux. An early study showed that patients who experience reflux only in the supine position have a higher incidence of esophagitis compared with patients who only refluxed in an upright position.⁷ Prolonged acid contact time increases the risk that esophagitis will become erosive. This was demonstrated in a study that concluded particularly that the presence of nocturnal reflux events lasting more than 5 minutes was a powerful predictor of erosive damage.⁶

Overall, approximately 7% to 12% of patients with chronic GERD develop Barrett’s esophagus compared with fewer than 1% of those in the general population.⁸ Potentially, more severe nocturnal symptoms may be among the factors that increase the risk of Barrett’s esophagus.^9,10 Esophageal adenocarcinoma also is more likely in patients with nocturnal episodes of GERD: In a national, population-based, case-controlled trial, an 11-fold increased risk for esophageal adenocarcinoma was reported in patients who experienced once-weekly episodes of nighttime heartburn, regurgitation, or both. Overall, an 8-fold increased risk of esophageal adenocarcinoma was observed in all patients with GERD.¹¹

Impact of nighttime episodes on sleep

Not surprisingly, sleep is significantly affected by nighttime GERD episodes. A recent Internet-based survey of full-time working adults in the United States identified 1002 patients with symptomatic GERD.¹² Using the validated GERD Symptom and Medication Questionnaire, symptomatic GERD was defined as a score of 10 or greater for at least one episode of heartburn or acid regurgitation within the past 7 days. Symptomatic nighttime GERD was defined as at least 2 nights with symptoms during the past 7 days. GERD-related sleep problems were twice as frequent in patients with nighttime compared with daytime GERD. Patients with nighttime episodes of GERD experienced GERD-related sleep impairment an average of 1.6 to 1.9 nights per week compared with 0.3 to 0.4 nights per week for the daytime GERD group.

In both groups, the most commonly reported sleep problem was awakening due to symptoms (75% vs 37%, respectively). Sixty-five percent of nighttime and 28% of daytime GERD patients indicated that GERD symptoms prevented them from feeling rested in the morning.¹² In addition, respondents with nighttime GERD experienced an additional 2.7 hours per week of lost work productivity when compared to those with daytime GERD.¹³ A similar survey also found that in those with nighttime GERD, the number of nights with sleep interference was associated with reduced work productivity.¹⁴

These results are consistent with 2 previous telephone surveys. In one survey, 13% of 1000 adults who experienced heartburn at least weekly had only nighttime episodes; 20% reported only daytime heartburn.¹⁵ Altogether, 79% of the heartburn sufferers reported experiencing heartburn at night. Of these, 75% reported that heartburn had a negative impact on sleep; 63% indicated that heartburn adversely affected their ability to sleep well; and 40% reported impaired functioning the next day. The prevalence of sleep disturbances increased directly with the incidence of nighttime heartburn.

The second telephone survey of persons with nighttime GERD had lower scores using the Short-Form 36 Health Survey (a measure of quality of life) than did persons with daytime GERD or controls (TABLE 1).⁴ In another study, the greatest differences between groups occurred in terms of physical and emotional role functioning, vitality, and general health.¹⁶ A comparison with other major disorders affirmed the substantial impairment in health-related quality of life caused by nighttime GERD (TABLE 2).⁴

In summary, although heartburn and regurgitation are common in daytime and nighttime GERD, patients with nighttime GERD are more likely to experience impaired sleep, fatigue, reduced work productivity, and decreased quality of life.

TABLE 1
Adjusted medical outcomes study Short-Form 36 Health Survey scores

TABLE 2
Mean medical outcomes study Short-Form 36 Health Survey scores

Diagnosis: evaluation of symptoms

Physicians should inquire specifically about GERD symptoms to ensure diagnosis, as the signs of GERD are often subtle, nonspecific, or judged to be trivial by patients. Symptoms of GERD may include esophageal or nonesophageal complaints, or both. Importantly, heartburn or regurgitation may be absent in many patients: One group of investigators reported that neither heartburn nor regurgitation was experienced by approximately half of all patients who had nonclassical symptoms of GERD.³

Nonesophageal symptoms associated with GERD

Laryngitis, laryngospasm, chronic cough, hoarseness, excessive throat clearing, and globus pharyngeus are common nonesophageal symptoms in patients with GERD (TABLE 3).^17,18 In a recent investigation, 86% and 77% of patients with nighttime and daytime episodes of GERD, respectively, reported one or more nonesophageal symptom. In patients experiencing GERD at night, the most common symptoms were sinusitis (52%), dry cough/throat clearing (49%), and snoring (47%). Symptom severity scores were significantly higher in the nighttime vs daytime GERD groups (2.42 vs 1.80, respectively).⁵

In a cross-sectional international population survey of 2202 randomly selected persons and 459 additional individuals with asthma, Gislason et al estimated the possible association between reported symptoms of nighttime GERD, sleep-disordered breathing, respiratory symptoms, and asthma. The investigators reported a 2- to 3-fold increased prevalence of asthma and other respiratory symptoms (such as wheezing, chest tightness, breathlessness, and nighttime cough) in patients with nighttime reflux.¹⁹

TABLE 3
Nonesophageal conditions associated with GERD

Patient history

The patient’s history is the primary focus of the diagnostic workup and the physician should explore patient risk factors for GERD. For patients with atypical symptoms of GERD, the history is especially important to determine the diagnosis.

The presence of at least one esophageal or non-esophageal sign and symptom should prompt consideration of GERD as the cause, and discussion with the patient may help classify GERD further. The symptoms of nighttime GERD range from mild to severe. Though they can be similar to the symptoms of daytime GERD, nocturnal symptoms may be exacerbated by lying down or may differ in their manifestation. Asking questions about a patient’s quality of sleep, with input from the patient’s sleep partner, if possible, is useful in assessing nighttime GERD (TABLE 4).

TABLE 4
Key questions in the assessment of nighttime GERD

Predictors of nighttime reflux

A high body mass index (BMI) may lead to a reduction in LES pressure and is a risk factor for GERD.^20,21 Social habits such as smoking and alcohol use are often cited as risk factors for GERD; however, data to confirm this premise are lacking.¹¹ Several other factors and the presence of some pulmonary disorders may be specific predictors and indications of nighttime GERD episodes.

A recent large prospective cohort study specifically evaluated predictors of heartburn during sleep. Symptoms of GERD were strongly associated with increased BMI, carbonated soft drink consumption (possibly due to low pH), snoring and daytime sleepiness, insomnia, hypertension, asthma, and usage of benzodiazepines (TABLE 5).²⁰ It was noted that the association of hypertension with nighttime heartburn likely is a reflection of factors associated with hypertension rather than hypertension itself. Possible factors of hypertension include antihypertensive medications, comorbidities, diet, and body habitus.²⁰

Several sleep-related and respiratory factors are associated with nighttime GERD. Among these, insomnia and sleepiness are probably consequences rather than causes of nighttime reflux. An association of GERD with obstructive sleep apnea has been established, although causality has not been determined. Similarly, asthma is clearly associated with GERD, but the extent of causality remains unclear. Nonetheless, nighttime GERD should be suspected in patients who present with one of these sleep disturbances, particularly obstructive sleep apnea, or adult-onset or difficult-to-treat asthma.²⁰

TABLE 5
Factors associated with nighttime GERD

Diagnostic tests for GERD

Various tests have been investigated for the diagnosis of all types of GERD, and there is no difference in the tests used when nighttime GERD is suspected. Endoscopy is an important diagnostic tool for either identifying or ruling out complications such as erosions or Barrett’s esophagus. Esophageal pH monitoring can be helpful in diagnosis.

Pathophysiology: potential differences between daytime and nighttime GERD

Several mechanisms have been established to contribute to the development of GERD. Included are transient LES relaxations and, less frequently, sustained LES pressure abnormalities. Other factors that contribute to the pathophysiology of GERD include hiatal hernia, which reduces LES pressure and impairs acid clearance, and poor esophageal clearance.²²

Despite their similarities, important pathophysiologic differences between daytime and nighttime gastroesophageal reflux can be seen. Increased acid secretion and gastric volume are associated with food consumption, so daytime reflux and associated symptoms tend to occur after meals. Nighttime gastroesophageal reflux occurs less frequently, but the episodes are of longer duration than those of daytime reflux, as a result of delayed acid clearance from the esophagus at night.^6,7,23

Sleep-related mechanisms combined with impairment of the LES and the supine position help explain the more common and severe symptoms and wider range of complications seen in nighttime compared with daytime GERD.

Protective processes impaired during sleep

Differences between daytime and nighttime GERD are thought to be due to the sleep state rather than just to differences in posture (TABLE 6).^24,25 Processes that occur normally during the day to facilitate refluxed acid clearance from the esophagus, such as swallowing and acid neutralization (via bicarbonate-containing salivation), are suppressed during sleep.²⁵

Saliva, composed of mucus, bicarbonate, and epidermal growth factor, neutralizes refluxed acid and protects esophageal tissue. Saliva production is diminished during sleep, with implications for GERD symptoms.^26,27 Swallowing is reduced during sleep and may not occur during deeper stages of sleep.²⁸ Absence of the voluntary swallow-initiated peristaltic wave of esophageal contractions during sleep also results in reduced volume clearance.²⁹

Delayed gastric emptying during sleep may result in increased gastric distention and contribute to the occurrence of nighttime reflux.^25,30

TABLE 6
Sleep-related mechanisms contributing to nighttime GERD

Effect of reduced consciousness

Reflux during sleep may be accompanied by a brief period of arousal, which helps to hasten esophageal clearance of refluxate and protect the airway against aspiration and acid exposure.²⁵ However, arousal does not occur in all reflux episodes, since the conscious perception of heartburn is absent during sleep. Consequently, the sleep-induced mechanisms are allowed to persist leading to prolonged periods of acid exposure.²⁵

Summary

For the purposes of understanding symptoms and facilitating diagnosis, GERD can be divided into daytime and nighttime GERD. Compared with daytime GERD, nighttime reflux episodes occur less frequently but are more prolonged. In addition, nighttime symptoms are more common and more severe, and esophageal and nonesophageal complications are more likely. The presence of severe symptoms or at least one esophageal and/or nonesophageal symptom should prompt an investigation of nighttime GERD. In doing so, the history and physical examination findings are the most helpful; laboratory values and other test results are generally less so. Physiologic alterations during sleep are thought to be the primary factors that contribute to nighttime symptoms.

EDITOR’S NOTE:
This article is meant to alert the reader to different symptomatology in GERD at night; therefore, treatment will not be discussed.

Prevalence estimates for gastroesophageal reflux disease (GERD) range from 8% to 40%, depending on the definition and diagnostic criteria.^1-4 While heartburn and regurgitation are considered the hallmark symptoms, GERD actually represents a spectrum of disorders that generally result from transient relaxations of the lower esophageal sphincter (LES), so that gastric refluxate comes into contact with the esophageal epithelium. Additionally, differences in rates of acid secretion and clearance and the time since food ingestion affect symptoms, potentially leading to differing presentations of GERD associated with daytime and nocturnal episodes. To facilitate accurate diagnosis of GERD, it may be helpful for clinicians to distinguish between the symptoms that occur during the day or in an upright position and those that occur at night or when a person is supine.⁴ This paper reviews the differences in symptoms and explains the pathophysiologic mechanisms involved.

Issues of GERD and quality of life

Patients’ quality of life and ability to function is negatively impacted by factors associated specifically with nocturnal episodes of GERD. Patients who experience GERD primarily at night may complain of sleep disturbances. Symptoms associated with nighttime GERD generally are more severe,⁵ and the complications more diverse and frequent,⁴ due to the prolonged length of nighttime reflux.⁶ For these reasons, determining if the underlying cause of a group of symptoms is nighttime episodes of GERD is an important treatment step.

Complications of reflux: associations with nighttime occurrences

Esophageal complications of GERD include erosive esophagitis, esophageal hemorrhage, ulceration, and strictures and appear to be more severe in patients with nighttime episodes of GERD than in those complaining of daytime reflux. An early study showed that patients who experience reflux only in the supine position have a higher incidence of esophagitis compared with patients who only refluxed in an upright position.⁷ Prolonged acid contact time increases the risk that esophagitis will become erosive. This was demonstrated in a study that concluded particularly that the presence of nocturnal reflux events lasting more than 5 minutes was a powerful predictor of erosive damage.⁶

Overall, approximately 7% to 12% of patients with chronic GERD develop Barrett’s esophagus compared with fewer than 1% of those in the general population.⁸ Potentially, more severe nocturnal symptoms may be among the factors that increase the risk of Barrett’s esophagus.^9,10 Esophageal adenocarcinoma also is more likely in patients with nocturnal episodes of GERD: In a national, population-based, case-controlled trial, an 11-fold increased risk for esophageal adenocarcinoma was reported in patients who experienced once-weekly episodes of nighttime heartburn, regurgitation, or both. Overall, an 8-fold increased risk of esophageal adenocarcinoma was observed in all patients with GERD.¹¹

Impact of nighttime episodes on sleep

Not surprisingly, sleep is significantly affected by nighttime GERD episodes. A recent Internet-based survey of full-time working adults in the United States identified 1002 patients with symptomatic GERD.¹² Using the validated GERD Symptom and Medication Questionnaire, symptomatic GERD was defined as a score of 10 or greater for at least one episode of heartburn or acid regurgitation within the past 7 days. Symptomatic nighttime GERD was defined as at least 2 nights with symptoms during the past 7 days. GERD-related sleep problems were twice as frequent in patients with nighttime compared with daytime GERD. Patients with nighttime episodes of GERD experienced GERD-related sleep impairment an average of 1.6 to 1.9 nights per week compared with 0.3 to 0.4 nights per week for the daytime GERD group.

In both groups, the most commonly reported sleep problem was awakening due to symptoms (75% vs 37%, respectively). Sixty-five percent of nighttime and 28% of daytime GERD patients indicated that GERD symptoms prevented them from feeling rested in the morning.¹² In addition, respondents with nighttime GERD experienced an additional 2.7 hours per week of lost work productivity when compared to those with daytime GERD.¹³ A similar survey also found that in those with nighttime GERD, the number of nights with sleep interference was associated with reduced work productivity.¹⁴

These results are consistent with 2 previous telephone surveys. In one survey, 13% of 1000 adults who experienced heartburn at least weekly had only nighttime episodes; 20% reported only daytime heartburn.¹⁵ Altogether, 79% of the heartburn sufferers reported experiencing heartburn at night. Of these, 75% reported that heartburn had a negative impact on sleep; 63% indicated that heartburn adversely affected their ability to sleep well; and 40% reported impaired functioning the next day. The prevalence of sleep disturbances increased directly with the incidence of nighttime heartburn.

The second telephone survey of persons with nighttime GERD had lower scores using the Short-Form 36 Health Survey (a measure of quality of life) than did persons with daytime GERD or controls (TABLE 1).⁴ In another study, the greatest differences between groups occurred in terms of physical and emotional role functioning, vitality, and general health.¹⁶ A comparison with other major disorders affirmed the substantial impairment in health-related quality of life caused by nighttime GERD (TABLE 2).⁴

In summary, although heartburn and regurgitation are common in daytime and nighttime GERD, patients with nighttime GERD are more likely to experience impaired sleep, fatigue, reduced work productivity, and decreased quality of life.

TABLE 1
Adjusted medical outcomes study Short-Form 36 Health Survey scores

TABLE 2
Mean medical outcomes study Short-Form 36 Health Survey scores

Diagnosis: evaluation of symptoms

Physicians should inquire specifically about GERD symptoms to ensure diagnosis, as the signs of GERD are often subtle, nonspecific, or judged to be trivial by patients. Symptoms of GERD may include esophageal or nonesophageal complaints, or both. Importantly, heartburn or regurgitation may be absent in many patients: One group of investigators reported that neither heartburn nor regurgitation was experienced by approximately half of all patients who had nonclassical symptoms of GERD.³

Nonesophageal symptoms associated with GERD

Laryngitis, laryngospasm, chronic cough, hoarseness, excessive throat clearing, and globus pharyngeus are common nonesophageal symptoms in patients with GERD (TABLE 3).^17,18 In a recent investigation, 86% and 77% of patients with nighttime and daytime episodes of GERD, respectively, reported one or more nonesophageal symptom. In patients experiencing GERD at night, the most common symptoms were sinusitis (52%), dry cough/throat clearing (49%), and snoring (47%). Symptom severity scores were significantly higher in the nighttime vs daytime GERD groups (2.42 vs 1.80, respectively).⁵

In a cross-sectional international population survey of 2202 randomly selected persons and 459 additional individuals with asthma, Gislason et al estimated the possible association between reported symptoms of nighttime GERD, sleep-disordered breathing, respiratory symptoms, and asthma. The investigators reported a 2- to 3-fold increased prevalence of asthma and other respiratory symptoms (such as wheezing, chest tightness, breathlessness, and nighttime cough) in patients with nighttime reflux.¹⁹

TABLE 3
Nonesophageal conditions associated with GERD

Patient history

The patient’s history is the primary focus of the diagnostic workup and the physician should explore patient risk factors for GERD. For patients with atypical symptoms of GERD, the history is especially important to determine the diagnosis.

The presence of at least one esophageal or non-esophageal sign and symptom should prompt consideration of GERD as the cause, and discussion with the patient may help classify GERD further. The symptoms of nighttime GERD range from mild to severe. Though they can be similar to the symptoms of daytime GERD, nocturnal symptoms may be exacerbated by lying down or may differ in their manifestation. Asking questions about a patient’s quality of sleep, with input from the patient’s sleep partner, if possible, is useful in assessing nighttime GERD (TABLE 4).

TABLE 4
Key questions in the assessment of nighttime GERD

Predictors of nighttime reflux

A high body mass index (BMI) may lead to a reduction in LES pressure and is a risk factor for GERD.^20,21 Social habits such as smoking and alcohol use are often cited as risk factors for GERD; however, data to confirm this premise are lacking.¹¹ Several other factors and the presence of some pulmonary disorders may be specific predictors and indications of nighttime GERD episodes.

A recent large prospective cohort study specifically evaluated predictors of heartburn during sleep. Symptoms of GERD were strongly associated with increased BMI, carbonated soft drink consumption (possibly due to low pH), snoring and daytime sleepiness, insomnia, hypertension, asthma, and usage of benzodiazepines (TABLE 5).²⁰ It was noted that the association of hypertension with nighttime heartburn likely is a reflection of factors associated with hypertension rather than hypertension itself. Possible factors of hypertension include antihypertensive medications, comorbidities, diet, and body habitus.²⁰

Several sleep-related and respiratory factors are associated with nighttime GERD. Among these, insomnia and sleepiness are probably consequences rather than causes of nighttime reflux. An association of GERD with obstructive sleep apnea has been established, although causality has not been determined. Similarly, asthma is clearly associated with GERD, but the extent of causality remains unclear. Nonetheless, nighttime GERD should be suspected in patients who present with one of these sleep disturbances, particularly obstructive sleep apnea, or adult-onset or difficult-to-treat asthma.²⁰

TABLE 5
Factors associated with nighttime GERD

Diagnostic tests for GERD

Various tests have been investigated for the diagnosis of all types of GERD, and there is no difference in the tests used when nighttime GERD is suspected. Endoscopy is an important diagnostic tool for either identifying or ruling out complications such as erosions or Barrett’s esophagus. Esophageal pH monitoring can be helpful in diagnosis.

Pathophysiology: potential differences between daytime and nighttime GERD

Several mechanisms have been established to contribute to the development of GERD. Included are transient LES relaxations and, less frequently, sustained LES pressure abnormalities. Other factors that contribute to the pathophysiology of GERD include hiatal hernia, which reduces LES pressure and impairs acid clearance, and poor esophageal clearance.²²

Despite their similarities, important pathophysiologic differences between daytime and nighttime gastroesophageal reflux can be seen. Increased acid secretion and gastric volume are associated with food consumption, so daytime reflux and associated symptoms tend to occur after meals. Nighttime gastroesophageal reflux occurs less frequently, but the episodes are of longer duration than those of daytime reflux, as a result of delayed acid clearance from the esophagus at night.^6,7,23

Sleep-related mechanisms combined with impairment of the LES and the supine position help explain the more common and severe symptoms and wider range of complications seen in nighttime compared with daytime GERD.

Protective processes impaired during sleep

Differences between daytime and nighttime GERD are thought to be due to the sleep state rather than just to differences in posture (TABLE 6).^24,25 Processes that occur normally during the day to facilitate refluxed acid clearance from the esophagus, such as swallowing and acid neutralization (via bicarbonate-containing salivation), are suppressed during sleep.²⁵

Saliva, composed of mucus, bicarbonate, and epidermal growth factor, neutralizes refluxed acid and protects esophageal tissue. Saliva production is diminished during sleep, with implications for GERD symptoms.^26,27 Swallowing is reduced during sleep and may not occur during deeper stages of sleep.²⁸ Absence of the voluntary swallow-initiated peristaltic wave of esophageal contractions during sleep also results in reduced volume clearance.²⁹

Delayed gastric emptying during sleep may result in increased gastric distention and contribute to the occurrence of nighttime reflux.^25,30

TABLE 6
Sleep-related mechanisms contributing to nighttime GERD

Effect of reduced consciousness

Reflux during sleep may be accompanied by a brief period of arousal, which helps to hasten esophageal clearance of refluxate and protect the airway against aspiration and acid exposure.²⁵ However, arousal does not occur in all reflux episodes, since the conscious perception of heartburn is absent during sleep. Consequently, the sleep-induced mechanisms are allowed to persist leading to prolonged periods of acid exposure.²⁵

Summary

For the purposes of understanding symptoms and facilitating diagnosis, GERD can be divided into daytime and nighttime GERD. Compared with daytime GERD, nighttime reflux episodes occur less frequently but are more prolonged. In addition, nighttime symptoms are more common and more severe, and esophageal and nonesophageal complications are more likely. The presence of severe symptoms or at least one esophageal and/or nonesophageal symptom should prompt an investigation of nighttime GERD. In doing so, the history and physical examination findings are the most helpful; laboratory values and other test results are generally less so. Physiologic alterations during sleep are thought to be the primary factors that contribute to nighttime symptoms.

EDITOR’S NOTE:
This article is meant to alert the reader to different symptomatology in GERD at night; therefore, treatment will not be discussed.

Since the approval of the 7-valent pneumococcal conjugate vaccine (PCV-7) for use in children younger than 24 months in February 2000, occurrences of acute otitis media (AOM) and the frequency of recurrent AOM have declined. Based on results from early clinical trials, PCV-7 may reduce total AOM by 6% to 8%, recurrent AOM by 10% to 26%, and tympanostomy tube placements by 24%.^1,2

Acute otitis media occurs most frequently in children between the ages of 6 months and 18 months. By the end of their first year, approximately 86% of children will experience at least 1 episode of AOM.³

The condition remains a leading reason for visits to pediatricians and family physicians in the United States.⁴ It accounted for 16 million visits in 2000.⁴ This is a decrease from almost 25 million visits in 1995, prior to use of PCV-7. Additionally, AOM is associated with significant costs: In 1995, the direct and indirect costs of AOM were estimated to be about $3 billion.⁵

Changes in pathogen frequency for AOM in the ERA of PCV-7

The true impact of PCV-7 on management practice is not characterized by the modest reduction in incidence of uncomplicated AOM but in the PCV-7–associated shift in causative pathogens. Pre-PCV-7, 40% to 50% of cases of AOM in young children were caused by Streptococcus pneumoniae, 20% to 30% by Haemophilus influenzae, and 10% to 15% by Moraxella catarrhalis.⁶ In studies conducted prior to 2000, diagnostic tympanocentesis isolated S pneumoniae from 25% to 55% of all middle ear aspirates from children with AOM.^6-8

Conversely, 1 study published in 2001 and 2 studies published in 2004 appear to document a reverse trend with the advent of the conjugate pneumococcal vaccine.^9,10 Compared with children studied in an earlier era, those vaccinated with PCV-7 may be more likely to have H influenzae isolates. These studies will be described in detail below.

Bacterial AOM: initial antibiotic therapy and specific pathogens

Current guidelines recommend amoxicillin (45 mg/kg/day) or high-dose amoxicillin (80-90 mg/kg/day) as initial therapy in presumed or documented bacterial AOM.⁵ Although amoxicillin is effective against pneumococcus and β-lactamase–negative strains of H influenzae, it is ineffective against β-lactamase–positive strains of H influenzae.⁹ Significant initial failures may point to a changing pathogen per population frequency. A 2004 review assessed children with continued (persistence of infection detected within 30 days after treatment completion) or refractory (clinical failure while receiving antimicrobial therapy) AOM who have received high-dose amoxicillin as initial empiric therapy. The authors noted that the rate of infection due to H influenzae has increased from 43% among those treated prior to the licensure of PCV-7 to 57% among those who received 2 or more doses of PCV-7.¹⁰

Evidence from the medical literature

Three studies provide the major evidence concerning the pathogen shift associated with the adoption of the PCV-7 conjugate vaccine:

• The Finnish Otitis Media Vaccine Trial²
• A published collection of clinical trial results from a rural practice in Kentucky in which 94% of children were immunized with PCV-7⁹
• A prospective study conducted in a suburban community-based private practice in Rochester, NY that evaluated children with persistent or nonresponsive AOM.¹⁰

The Finnish Otitis Media Vaccine Trial

In this trial, 1662 infants received either the PCV-7 vaccine or a control vaccine at ages 2, 4, 6, and 12 months and were monitored from ages 6.5 months to 24 months.² An overall 6.9% reduction in episodes of clinical AOM were diagnosed (n=1251) in PCV-7–vaccinated children compared with the control group (n=1345). This suggested that fewer AOM cases were caused by the S pneumoniae vaccine serotypes than nonvaccine serotypes. The bacteriologic findings in the samples of middle ear fluid taken during 93% of the visits for AOM (TABLE 1) show a 34% reduction in culture-confirmed episodes in the PCV-7–vaccinated group, a decrease of more than 50% in pneumococcal AOM episodes caused by vaccine or vaccine cross-reactive serotypes, a 33% increase in infections caused by other pneumococcal serotypes, and an 11% increase in the proportion of AOM cases due to H influenzae.²

TABLE 1

Finnish Otitis Media Vaccine Trial: Causes of AOM Episodes and Impact of PCV-7 Immunization on Incidence

Study Results From a Rural Kentucky Practice

In this practice, data on isolates from middle ear fluid were collected in children with severe or refractory AOM aged 7 to 24 months.⁹ Data were obtained from 1992 to 1998, before the introduction of PCV-7, and from 2000 to 2003, following immunization with 3 or 4 doses of PCV-7 during the first 18 months of life.

As shown in TABLE 2, the pre-PCV-7 group of children (N=336; 1992-1998) had a proportion of 48% culture-confirmed pneumococcus vs a proportion of 31% in the PCV-7-vaccinated group (N=83; 2000-2003), a 17% decrease. The decrease in proportion of AOM episodes resulting from vaccine serotypes was 34%.

In this investigation, 28% of the pre-PCV-7 group and 34% of the post-PCV-7 group had received antibiotic therapy within the previous 3 days. Additionally, 59% and 76%, respectively, had received antibiotic therapy within the preceding 30 days. There were increases of 30% in vaccine cross-reactive serotypes and 45% in nonvaccine serotypes. Vaccine cross-reactive serotypes 6A and 19A accounted for most of the penicillin-nonsusceptible S pneumoniae strains in the vaccinated population.

Most impressive, however, in the post-PCV-7 group, was that gram-negative bacteria, mainly H influenzae, accounted for two thirds of AOM isolates, an increase from 41% in the pre-PCV-7 group to 56% in the vaccinated group. A 56% increase was noted in β-lactamase–positive organisms from the pre-PCV-7 group to the post-PCV-7 group. The combined H influenzae and M catarrhalis β-lactamase–producing organisms accounted for nearly half of all isolates.⁹

TABLE 2

Results From a Rural Kentucky Practice: Change in AOM Microbiology From Pre-PCV-7 (1992–1998) to Post-PCV-7 (2000–2003)

The Prospective Rochester, New York Study

Changes in pre- and post-PVC-7 patterns also were seen in a prospective study of 551 children with persistent or nonresponsive AOM (defined as nonresponders after 1 or 2 empiric antibiotic courses or failures after 48 hours of treatment). These children underwent tympanocentesis to identify bacterial isolates during the 9-year period from 1995 to 2003.¹⁰

From 1995 to 1997, enrollees received a standard dose of amoxicillin (40-50 mg/kg, divided into 3 doses daily) as initial empiric treatment. From 1998 to 2000 and 2001 to 2003, all children received high-dose amoxicillin (80-100 mg/kg, divided into twice-daily doses).

During the latter period, the children also were vaccinated with PCV-7, with 63% receiving the primary series of 3 doses and 10% receiving the booster dose. In this investigation, shortages in vaccine supply, discussed below, caused vaccination schedules to be compromised.

Study results (TABLE 3) show that in the post-PCV-7 group, there was a 13% decrease in the proportion of S pneumoniae isolates and a 14% increase in the proportion of H influenzae isolates compared with the pre-PCV-7 group (1998-2000 enrollees). An increase of 22% for β-lactamase–positive bacteria was also observed, along with a trend toward an increased proportion of penicillin-susceptible S pneumoniae isolates (58% vs 72%; P=.017) post-PCV-7.¹⁰ A 24% reduction (P=.009) in the frequency of the diagnosis of persistent or AOM treatment failure occurred in the period after PCV-7 vaccination. These changes were considered to be the result of the use of the conjugate pneumococcal vaccine rather than of the change in amoxicillin dosing.¹⁰

TABLE 3

The Prospective Rochester, New York Study: Pathogens Isolated in Persistent AOM and AOM Treatment Failure Pre- and Post-PCV-7

Pneumococcal serotype shifts

In addition to the change in causative pathogens, use of the conjugate pneumococcal vaccine appears to have led to a significant shift in the pneumococcal strains causing AOM. Studies at urban medical centers and in the Kentucky practice documented an increase in the proportion of nonvaccine serotypes, accounting for 32% to 38% of pneumococcal AOM.^10-12 A 33% increase was seen in the Finnish Trial.² These nonvaccine pneumococcal serotypes do not carry the same level of resistance seen with those serotypes included in PCV-7.

PCV-7 conjugate vaccine

The PCV-7 conjugate vaccine was approved for use in February 2000. It is a 7-valent pneumococcal conjugate of the capsular antigens of the S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, individually conjugated to diphtheria CRM197 protein.¹³ These serotypes have been responsible for approximately 80% of invasive pneumococcal disease in children younger than 6 years in the United States.^13,14 They also accounted for 74% of penicillin-susceptible S pneumoniae and 100% of pneumococci with high-level penicillin resistance isolated from children younger than age 6 years with invasive disease during a 1993-1994 surveillance by the Centers for Disease Control and Prevention (CDC).¹³

Mechanism of Action and Recommended Immunization Schedule

The conjugate vaccine is converted to a T-cell–dependent antigen, antibody formation is enhanced, and memory B cells are primed.¹⁴

The recommended immunization schedule was established as 3 primary doses at ages 2, 4, and 6 months and a booster dose at 12 to 15 months.¹ It is the first multivalent pneumococcal vaccine approved for use in children younger than 24 months.

An 89% reduction in invasive pneumococcal disease was observed in children receiving 1 or more doses, and the vaccine appears to reduce nasopharyngeal carriage of vaccine serotypes.^15,16

The older 23-valent polysaccharide vaccine does not stimulate good response in children younger than 2 years of age¹⁴ and does not reduce mucosal carriage or limit the spread of resistant strains.¹⁵

PCV-7 Supply Since 2000

In August 2001, a serious shortage of the vaccine developed in 34 state immunization programs.¹⁷ The following month, the CDC advised physicians to administer it only to children younger than 12 months and to those aged 1 to 5 years at increased risk of pneumococcal disease.¹⁸ As demand continued despite the change in recommendations, the CDC further changed recommendations to conserve vaccine supply, first suspending the fourth dose temporarily in healthy children¹⁹ and then discontinuing both the third and fourth doses.¹¹ In July 2004, production problems seemed to have resolved; the CDC recommended that every child receive 3 doses. In September, supplies were adequate for return to the 4-dose schedule.¹² As of June 2004, 67.7% of children aged 24 months had received 3 or more doses of PCV-7.²⁰ Thus, the effects of PCV-7 on the changing microbiology of AOM may only now, at the end of 2005, be fully realized.

Herd Immunity and Reduction in Carriage

Despite the shortages of vaccine during the first years of use, evidence of herd immunity and a decrease in antibiotic resistance in pneumococcal pathogens has been reported throughout the United States.^21,22 A 29% decrease in the rate of pneumococcal disease in both young children and adults has also been observed, along with a 35% reduction in the rate of disease caused by nonpenicillin-susceptible pneumococcal strains.²¹ The reduction in carriage among vaccinated children may be the reason.^21,22 Because of the impact of PCV-7, it will be important to record immunization history when collecting AOM data.

AOM treatment choices

The basis of recommendations for treating AOM depends on the presumed responsible pathogens, their susceptibility to antibiotics, and concerns for developing resistance, all influenced by clinical trial data. In practice, however, empiric choices are often made based on knowledge of local resistance patterns and of other patient characteristics; that is cost concerns, adverse event profiles, need to avoid initial treatment failure, adherence issues (eg, taste or palatability), convenience, and duration of dosing regimen.

All current guidelines recommend oral amoxicillin as first-line therapy in documented or presumed bacterial AOM. The 2004 American Academy of Pediatrics/American Academy of Family Physicians’ (AAP/AAFP) guidelines⁴ recommended increasing the dosage used for empiric treatment from 40 to 45 mg/kg/day to 80 to 90 mg/kg/day for all children. This was a result of concerns about the prevalence of penicillin-resistant S pneumoniae for which standard-dose amoxicillin is inadequate.²³

The guidelines were written and published before the data from the Kentucky and New York studies were available; therefore, although the guidelines recommended that empiric treatment of bacterial AOM should target S pneumoniae, H influenzae, and M catarrhalis, the pathogen shift discussed previously might today produce a modified antibiotic selection paradigm. The pathogen mix in persistent or recurrent AOM has already led to a guideline recommendation for high-dose amoxicillin/clavulanate, 90/6.4 mg/kg/day, cefdinir, cefprozil, cefpodoxime, cefuroxime, or ceftriaxone in these patients.²³

If an increase in the proportion of β-lactamase–producing pathogens due to PCV-7 occurs, amoxicillin may no longer be the best first choice.

Selecting Among Recommended Antibiotic Choices

As antibiotic preparations for treating bacterial AOM are oral suspensions, taste is a major factor for pediatric patients. TABLE 4 summarizes comparative taste ratings for antibiotic suspensions based on several studies and shows the range, from those that can enhance compliance to those that discourage compliance.²³

Adverse events, especially diarrhea, nausea/vomiting, and gastritis, are also of concern. These are shortcomings of amoxicillin/clavulanate, which has a higher incidence of diarrhea and nausea than cephalosporins.²⁴

Dosing frequency is also a factor among recommended agents. Amoxicillin, amoxicillin/clavulanate, cefprozil, and cefpodoxime require twice-daily dosing. Cefdinir can be effective at once-daily dosing.²⁴

Duration of approved therapy is perhaps the most critical selection factor given the reality of patient behaviors. Cefpodoxime and cefdinir are the only 2 FDA-approved agents for 5-day treatment of bacterial AOM that are also guideline-recommended.

TABLE 4

Compliance-Enhancing Ranking of Antibiotic Suspensions

Choices for Effective Initial Therapy

Considering the changing microbial population in bacterial AOM and the increasing concern of effectiveness of amoxicillin and other antibiotics against β-lactamase–producing H influenzae, the choice of therapy may need modification. Specifically, that may mean changing the choice of effective antibiotic, taking into consideration the compliance-enhancing advantages of available options.

Based on efficacy, the overall prevalence of antibiotic-resistant AOM pathogens for PCV-7-vaccinated children, the potential for adverse effects, and patient compliance issues, Block and Harrison developed an algorithm (FIGURE) for the management of AOM diagnosed by strict criteria in an otherwise healthy child between 4 months and 36 months old.²⁴ As the environment of AOM evolves, the choices for treatment must be not only effective but also the best and most appropriate.

FIGURE Antibiotic Choices for Acute Otitis Media in the 2000s

Since the approval of the 7-valent pneumococcal conjugate vaccine (PCV-7) for use in children younger than 24 months in February 2000, occurrences of acute otitis media (AOM) and the frequency of recurrent AOM have declined. Based on results from early clinical trials, PCV-7 may reduce total AOM by 6% to 8%, recurrent AOM by 10% to 26%, and tympanostomy tube placements by 24%.^1,2

Acute otitis media occurs most frequently in children between the ages of 6 months and 18 months. By the end of their first year, approximately 86% of children will experience at least 1 episode of AOM.³

The condition remains a leading reason for visits to pediatricians and family physicians in the United States.⁴ It accounted for 16 million visits in 2000.⁴ This is a decrease from almost 25 million visits in 1995, prior to use of PCV-7. Additionally, AOM is associated with significant costs: In 1995, the direct and indirect costs of AOM were estimated to be about $3 billion.⁵

Changes in pathogen frequency for AOM in the ERA of PCV-7

The true impact of PCV-7 on management practice is not characterized by the modest reduction in incidence of uncomplicated AOM but in the PCV-7–associated shift in causative pathogens. Pre-PCV-7, 40% to 50% of cases of AOM in young children were caused by Streptococcus pneumoniae, 20% to 30% by Haemophilus influenzae, and 10% to 15% by Moraxella catarrhalis.⁶ In studies conducted prior to 2000, diagnostic tympanocentesis isolated S pneumoniae from 25% to 55% of all middle ear aspirates from children with AOM.^6-8

Conversely, 1 study published in 2001 and 2 studies published in 2004 appear to document a reverse trend with the advent of the conjugate pneumococcal vaccine.^9,10 Compared with children studied in an earlier era, those vaccinated with PCV-7 may be more likely to have H influenzae isolates. These studies will be described in detail below.

Bacterial AOM: initial antibiotic therapy and specific pathogens

Current guidelines recommend amoxicillin (45 mg/kg/day) or high-dose amoxicillin (80-90 mg/kg/day) as initial therapy in presumed or documented bacterial AOM.⁵ Although amoxicillin is effective against pneumococcus and β-lactamase–negative strains of H influenzae, it is ineffective against β-lactamase–positive strains of H influenzae.⁹ Significant initial failures may point to a changing pathogen per population frequency. A 2004 review assessed children with continued (persistence of infection detected within 30 days after treatment completion) or refractory (clinical failure while receiving antimicrobial therapy) AOM who have received high-dose amoxicillin as initial empiric therapy. The authors noted that the rate of infection due to H influenzae has increased from 43% among those treated prior to the licensure of PCV-7 to 57% among those who received 2 or more doses of PCV-7.¹⁰

Evidence from the medical literature

Three studies provide the major evidence concerning the pathogen shift associated with the adoption of the PCV-7 conjugate vaccine:

• The Finnish Otitis Media Vaccine Trial²
• A published collection of clinical trial results from a rural practice in Kentucky in which 94% of children were immunized with PCV-7⁹
• A prospective study conducted in a suburban community-based private practice in Rochester, NY that evaluated children with persistent or nonresponsive AOM.¹⁰

The Finnish Otitis Media Vaccine Trial

In this trial, 1662 infants received either the PCV-7 vaccine or a control vaccine at ages 2, 4, 6, and 12 months and were monitored from ages 6.5 months to 24 months.² An overall 6.9% reduction in episodes of clinical AOM were diagnosed (n=1251) in PCV-7–vaccinated children compared with the control group (n=1345). This suggested that fewer AOM cases were caused by the S pneumoniae vaccine serotypes than nonvaccine serotypes. The bacteriologic findings in the samples of middle ear fluid taken during 93% of the visits for AOM (TABLE 1) show a 34% reduction in culture-confirmed episodes in the PCV-7–vaccinated group, a decrease of more than 50% in pneumococcal AOM episodes caused by vaccine or vaccine cross-reactive serotypes, a 33% increase in infections caused by other pneumococcal serotypes, and an 11% increase in the proportion of AOM cases due to H influenzae.²

TABLE 1

Finnish Otitis Media Vaccine Trial: Causes of AOM Episodes and Impact of PCV-7 Immunization on Incidence

Study Results From a Rural Kentucky Practice

In this practice, data on isolates from middle ear fluid were collected in children with severe or refractory AOM aged 7 to 24 months.⁹ Data were obtained from 1992 to 1998, before the introduction of PCV-7, and from 2000 to 2003, following immunization with 3 or 4 doses of PCV-7 during the first 18 months of life.

As shown in TABLE 2, the pre-PCV-7 group of children (N=336; 1992-1998) had a proportion of 48% culture-confirmed pneumococcus vs a proportion of 31% in the PCV-7-vaccinated group (N=83; 2000-2003), a 17% decrease. The decrease in proportion of AOM episodes resulting from vaccine serotypes was 34%.

In this investigation, 28% of the pre-PCV-7 group and 34% of the post-PCV-7 group had received antibiotic therapy within the previous 3 days. Additionally, 59% and 76%, respectively, had received antibiotic therapy within the preceding 30 days. There were increases of 30% in vaccine cross-reactive serotypes and 45% in nonvaccine serotypes. Vaccine cross-reactive serotypes 6A and 19A accounted for most of the penicillin-nonsusceptible S pneumoniae strains in the vaccinated population.

Most impressive, however, in the post-PCV-7 group, was that gram-negative bacteria, mainly H influenzae, accounted for two thirds of AOM isolates, an increase from 41% in the pre-PCV-7 group to 56% in the vaccinated group. A 56% increase was noted in β-lactamase–positive organisms from the pre-PCV-7 group to the post-PCV-7 group. The combined H influenzae and M catarrhalis β-lactamase–producing organisms accounted for nearly half of all isolates.⁹

TABLE 2

Results From a Rural Kentucky Practice: Change in AOM Microbiology From Pre-PCV-7 (1992–1998) to Post-PCV-7 (2000–2003)

The Prospective Rochester, New York Study

Changes in pre- and post-PVC-7 patterns also were seen in a prospective study of 551 children with persistent or nonresponsive AOM (defined as nonresponders after 1 or 2 empiric antibiotic courses or failures after 48 hours of treatment). These children underwent tympanocentesis to identify bacterial isolates during the 9-year period from 1995 to 2003.¹⁰

From 1995 to 1997, enrollees received a standard dose of amoxicillin (40-50 mg/kg, divided into 3 doses daily) as initial empiric treatment. From 1998 to 2000 and 2001 to 2003, all children received high-dose amoxicillin (80-100 mg/kg, divided into twice-daily doses).

During the latter period, the children also were vaccinated with PCV-7, with 63% receiving the primary series of 3 doses and 10% receiving the booster dose. In this investigation, shortages in vaccine supply, discussed below, caused vaccination schedules to be compromised.

Study results (TABLE 3) show that in the post-PCV-7 group, there was a 13% decrease in the proportion of S pneumoniae isolates and a 14% increase in the proportion of H influenzae isolates compared with the pre-PCV-7 group (1998-2000 enrollees). An increase of 22% for β-lactamase–positive bacteria was also observed, along with a trend toward an increased proportion of penicillin-susceptible S pneumoniae isolates (58% vs 72%; P=.017) post-PCV-7.¹⁰ A 24% reduction (P=.009) in the frequency of the diagnosis of persistent or AOM treatment failure occurred in the period after PCV-7 vaccination. These changes were considered to be the result of the use of the conjugate pneumococcal vaccine rather than of the change in amoxicillin dosing.¹⁰

TABLE 3

The Prospective Rochester, New York Study: Pathogens Isolated in Persistent AOM and AOM Treatment Failure Pre- and Post-PCV-7

Pneumococcal serotype shifts

In addition to the change in causative pathogens, use of the conjugate pneumococcal vaccine appears to have led to a significant shift in the pneumococcal strains causing AOM. Studies at urban medical centers and in the Kentucky practice documented an increase in the proportion of nonvaccine serotypes, accounting for 32% to 38% of pneumococcal AOM.^10-12 A 33% increase was seen in the Finnish Trial.² These nonvaccine pneumococcal serotypes do not carry the same level of resistance seen with those serotypes included in PCV-7.

PCV-7 conjugate vaccine

The PCV-7 conjugate vaccine was approved for use in February 2000. It is a 7-valent pneumococcal conjugate of the capsular antigens of the S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, individually conjugated to diphtheria CRM197 protein.¹³ These serotypes have been responsible for approximately 80% of invasive pneumococcal disease in children younger than 6 years in the United States.^13,14 They also accounted for 74% of penicillin-susceptible S pneumoniae and 100% of pneumococci with high-level penicillin resistance isolated from children younger than age 6 years with invasive disease during a 1993-1994 surveillance by the Centers for Disease Control and Prevention (CDC).¹³

Mechanism of Action and Recommended Immunization Schedule

The conjugate vaccine is converted to a T-cell–dependent antigen, antibody formation is enhanced, and memory B cells are primed.¹⁴

The recommended immunization schedule was established as 3 primary doses at ages 2, 4, and 6 months and a booster dose at 12 to 15 months.¹ It is the first multivalent pneumococcal vaccine approved for use in children younger than 24 months.

An 89% reduction in invasive pneumococcal disease was observed in children receiving 1 or more doses, and the vaccine appears to reduce nasopharyngeal carriage of vaccine serotypes.^15,16

The older 23-valent polysaccharide vaccine does not stimulate good response in children younger than 2 years of age¹⁴ and does not reduce mucosal carriage or limit the spread of resistant strains.¹⁵

PCV-7 Supply Since 2000

In August 2001, a serious shortage of the vaccine developed in 34 state immunization programs.¹⁷ The following month, the CDC advised physicians to administer it only to children younger than 12 months and to those aged 1 to 5 years at increased risk of pneumococcal disease.¹⁸ As demand continued despite the change in recommendations, the CDC further changed recommendations to conserve vaccine supply, first suspending the fourth dose temporarily in healthy children¹⁹ and then discontinuing both the third and fourth doses.¹¹ In July 2004, production problems seemed to have resolved; the CDC recommended that every child receive 3 doses. In September, supplies were adequate for return to the 4-dose schedule.¹² As of June 2004, 67.7% of children aged 24 months had received 3 or more doses of PCV-7.²⁰ Thus, the effects of PCV-7 on the changing microbiology of AOM may only now, at the end of 2005, be fully realized.

Herd Immunity and Reduction in Carriage

Despite the shortages of vaccine during the first years of use, evidence of herd immunity and a decrease in antibiotic resistance in pneumococcal pathogens has been reported throughout the United States.^21,22 A 29% decrease in the rate of pneumococcal disease in both young children and adults has also been observed, along with a 35% reduction in the rate of disease caused by nonpenicillin-susceptible pneumococcal strains.²¹ The reduction in carriage among vaccinated children may be the reason.^21,22 Because of the impact of PCV-7, it will be important to record immunization history when collecting AOM data.

AOM treatment choices

The basis of recommendations for treating AOM depends on the presumed responsible pathogens, their susceptibility to antibiotics, and concerns for developing resistance, all influenced by clinical trial data. In practice, however, empiric choices are often made based on knowledge of local resistance patterns and of other patient characteristics; that is cost concerns, adverse event profiles, need to avoid initial treatment failure, adherence issues (eg, taste or palatability), convenience, and duration of dosing regimen.

All current guidelines recommend oral amoxicillin as first-line therapy in documented or presumed bacterial AOM. The 2004 American Academy of Pediatrics/American Academy of Family Physicians’ (AAP/AAFP) guidelines⁴ recommended increasing the dosage used for empiric treatment from 40 to 45 mg/kg/day to 80 to 90 mg/kg/day for all children. This was a result of concerns about the prevalence of penicillin-resistant S pneumoniae for which standard-dose amoxicillin is inadequate.²³

The guidelines were written and published before the data from the Kentucky and New York studies were available; therefore, although the guidelines recommended that empiric treatment of bacterial AOM should target S pneumoniae, H influenzae, and M catarrhalis, the pathogen shift discussed previously might today produce a modified antibiotic selection paradigm. The pathogen mix in persistent or recurrent AOM has already led to a guideline recommendation for high-dose amoxicillin/clavulanate, 90/6.4 mg/kg/day, cefdinir, cefprozil, cefpodoxime, cefuroxime, or ceftriaxone in these patients.²³

If an increase in the proportion of β-lactamase–producing pathogens due to PCV-7 occurs, amoxicillin may no longer be the best first choice.

Selecting Among Recommended Antibiotic Choices

As antibiotic preparations for treating bacterial AOM are oral suspensions, taste is a major factor for pediatric patients. TABLE 4 summarizes comparative taste ratings for antibiotic suspensions based on several studies and shows the range, from those that can enhance compliance to those that discourage compliance.²³

Adverse events, especially diarrhea, nausea/vomiting, and gastritis, are also of concern. These are shortcomings of amoxicillin/clavulanate, which has a higher incidence of diarrhea and nausea than cephalosporins.²⁴

Dosing frequency is also a factor among recommended agents. Amoxicillin, amoxicillin/clavulanate, cefprozil, and cefpodoxime require twice-daily dosing. Cefdinir can be effective at once-daily dosing.²⁴

Duration of approved therapy is perhaps the most critical selection factor given the reality of patient behaviors. Cefpodoxime and cefdinir are the only 2 FDA-approved agents for 5-day treatment of bacterial AOM that are also guideline-recommended.

TABLE 4

Compliance-Enhancing Ranking of Antibiotic Suspensions

Choices for Effective Initial Therapy

Considering the changing microbial population in bacterial AOM and the increasing concern of effectiveness of amoxicillin and other antibiotics against β-lactamase–producing H influenzae, the choice of therapy may need modification. Specifically, that may mean changing the choice of effective antibiotic, taking into consideration the compliance-enhancing advantages of available options.

Based on efficacy, the overall prevalence of antibiotic-resistant AOM pathogens for PCV-7-vaccinated children, the potential for adverse effects, and patient compliance issues, Block and Harrison developed an algorithm (FIGURE) for the management of AOM diagnosed by strict criteria in an otherwise healthy child between 4 months and 36 months old.²⁴ As the environment of AOM evolves, the choices for treatment must be not only effective but also the best and most appropriate.

FIGURE Antibiotic Choices for Acute Otitis Media in the 2000s

Since the approval of the 7-valent pneumococcal conjugate vaccine (PCV-7) for use in children younger than 24 months in February 2000, occurrences of acute otitis media (AOM) and the frequency of recurrent AOM have declined. Based on results from early clinical trials, PCV-7 may reduce total AOM by 6% to 8%, recurrent AOM by 10% to 26%, and tympanostomy tube placements by 24%.^1,2

Acute otitis media occurs most frequently in children between the ages of 6 months and 18 months. By the end of their first year, approximately 86% of children will experience at least 1 episode of AOM.³

The condition remains a leading reason for visits to pediatricians and family physicians in the United States.⁴ It accounted for 16 million visits in 2000.⁴ This is a decrease from almost 25 million visits in 1995, prior to use of PCV-7. Additionally, AOM is associated with significant costs: In 1995, the direct and indirect costs of AOM were estimated to be about $3 billion.⁵

Changes in pathogen frequency for AOM in the ERA of PCV-7

The true impact of PCV-7 on management practice is not characterized by the modest reduction in incidence of uncomplicated AOM but in the PCV-7–associated shift in causative pathogens. Pre-PCV-7, 40% to 50% of cases of AOM in young children were caused by Streptococcus pneumoniae, 20% to 30% by Haemophilus influenzae, and 10% to 15% by Moraxella catarrhalis.⁶ In studies conducted prior to 2000, diagnostic tympanocentesis isolated S pneumoniae from 25% to 55% of all middle ear aspirates from children with AOM.^6-8

Conversely, 1 study published in 2001 and 2 studies published in 2004 appear to document a reverse trend with the advent of the conjugate pneumococcal vaccine.^9,10 Compared with children studied in an earlier era, those vaccinated with PCV-7 may be more likely to have H influenzae isolates. These studies will be described in detail below.

Bacterial AOM: initial antibiotic therapy and specific pathogens

Current guidelines recommend amoxicillin (45 mg/kg/day) or high-dose amoxicillin (80-90 mg/kg/day) as initial therapy in presumed or documented bacterial AOM.⁵ Although amoxicillin is effective against pneumococcus and β-lactamase–negative strains of H influenzae, it is ineffective against β-lactamase–positive strains of H influenzae.⁹ Significant initial failures may point to a changing pathogen per population frequency. A 2004 review assessed children with continued (persistence of infection detected within 30 days after treatment completion) or refractory (clinical failure while receiving antimicrobial therapy) AOM who have received high-dose amoxicillin as initial empiric therapy. The authors noted that the rate of infection due to H influenzae has increased from 43% among those treated prior to the licensure of PCV-7 to 57% among those who received 2 or more doses of PCV-7.¹⁰

Evidence from the medical literature

Three studies provide the major evidence concerning the pathogen shift associated with the adoption of the PCV-7 conjugate vaccine:

• The Finnish Otitis Media Vaccine Trial²
• A published collection of clinical trial results from a rural practice in Kentucky in which 94% of children were immunized with PCV-7⁹
• A prospective study conducted in a suburban community-based private practice in Rochester, NY that evaluated children with persistent or nonresponsive AOM.¹⁰

The Finnish Otitis Media Vaccine Trial

In this trial, 1662 infants received either the PCV-7 vaccine or a control vaccine at ages 2, 4, 6, and 12 months and were monitored from ages 6.5 months to 24 months.² An overall 6.9% reduction in episodes of clinical AOM were diagnosed (n=1251) in PCV-7–vaccinated children compared with the control group (n=1345). This suggested that fewer AOM cases were caused by the S pneumoniae vaccine serotypes than nonvaccine serotypes. The bacteriologic findings in the samples of middle ear fluid taken during 93% of the visits for AOM (TABLE 1) show a 34% reduction in culture-confirmed episodes in the PCV-7–vaccinated group, a decrease of more than 50% in pneumococcal AOM episodes caused by vaccine or vaccine cross-reactive serotypes, a 33% increase in infections caused by other pneumococcal serotypes, and an 11% increase in the proportion of AOM cases due to H influenzae.²

TABLE 1

Finnish Otitis Media Vaccine Trial: Causes of AOM Episodes and Impact of PCV-7 Immunization on Incidence

Study Results From a Rural Kentucky Practice

In this practice, data on isolates from middle ear fluid were collected in children with severe or refractory AOM aged 7 to 24 months.⁹ Data were obtained from 1992 to 1998, before the introduction of PCV-7, and from 2000 to 2003, following immunization with 3 or 4 doses of PCV-7 during the first 18 months of life.

As shown in TABLE 2, the pre-PCV-7 group of children (N=336; 1992-1998) had a proportion of 48% culture-confirmed pneumococcus vs a proportion of 31% in the PCV-7-vaccinated group (N=83; 2000-2003), a 17% decrease. The decrease in proportion of AOM episodes resulting from vaccine serotypes was 34%.

In this investigation, 28% of the pre-PCV-7 group and 34% of the post-PCV-7 group had received antibiotic therapy within the previous 3 days. Additionally, 59% and 76%, respectively, had received antibiotic therapy within the preceding 30 days. There were increases of 30% in vaccine cross-reactive serotypes and 45% in nonvaccine serotypes. Vaccine cross-reactive serotypes 6A and 19A accounted for most of the penicillin-nonsusceptible S pneumoniae strains in the vaccinated population.

Most impressive, however, in the post-PCV-7 group, was that gram-negative bacteria, mainly H influenzae, accounted for two thirds of AOM isolates, an increase from 41% in the pre-PCV-7 group to 56% in the vaccinated group. A 56% increase was noted in β-lactamase–positive organisms from the pre-PCV-7 group to the post-PCV-7 group. The combined H influenzae and M catarrhalis β-lactamase–producing organisms accounted for nearly half of all isolates.⁹

TABLE 2

Results From a Rural Kentucky Practice: Change in AOM Microbiology From Pre-PCV-7 (1992–1998) to Post-PCV-7 (2000–2003)

The Prospective Rochester, New York Study

Changes in pre- and post-PVC-7 patterns also were seen in a prospective study of 551 children with persistent or nonresponsive AOM (defined as nonresponders after 1 or 2 empiric antibiotic courses or failures after 48 hours of treatment). These children underwent tympanocentesis to identify bacterial isolates during the 9-year period from 1995 to 2003.¹⁰

From 1995 to 1997, enrollees received a standard dose of amoxicillin (40-50 mg/kg, divided into 3 doses daily) as initial empiric treatment. From 1998 to 2000 and 2001 to 2003, all children received high-dose amoxicillin (80-100 mg/kg, divided into twice-daily doses).

During the latter period, the children also were vaccinated with PCV-7, with 63% receiving the primary series of 3 doses and 10% receiving the booster dose. In this investigation, shortages in vaccine supply, discussed below, caused vaccination schedules to be compromised.

Study results (TABLE 3) show that in the post-PCV-7 group, there was a 13% decrease in the proportion of S pneumoniae isolates and a 14% increase in the proportion of H influenzae isolates compared with the pre-PCV-7 group (1998-2000 enrollees). An increase of 22% for β-lactamase–positive bacteria was also observed, along with a trend toward an increased proportion of penicillin-susceptible S pneumoniae isolates (58% vs 72%; P=.017) post-PCV-7.¹⁰ A 24% reduction (P=.009) in the frequency of the diagnosis of persistent or AOM treatment failure occurred in the period after PCV-7 vaccination. These changes were considered to be the result of the use of the conjugate pneumococcal vaccine rather than of the change in amoxicillin dosing.¹⁰

TABLE 3

The Prospective Rochester, New York Study: Pathogens Isolated in Persistent AOM and AOM Treatment Failure Pre- and Post-PCV-7

Pneumococcal serotype shifts

In addition to the change in causative pathogens, use of the conjugate pneumococcal vaccine appears to have led to a significant shift in the pneumococcal strains causing AOM. Studies at urban medical centers and in the Kentucky practice documented an increase in the proportion of nonvaccine serotypes, accounting for 32% to 38% of pneumococcal AOM.^10-12 A 33% increase was seen in the Finnish Trial.² These nonvaccine pneumococcal serotypes do not carry the same level of resistance seen with those serotypes included in PCV-7.

PCV-7 conjugate vaccine

The PCV-7 conjugate vaccine was approved for use in February 2000. It is a 7-valent pneumococcal conjugate of the capsular antigens of the S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, individually conjugated to diphtheria CRM197 protein.¹³ These serotypes have been responsible for approximately 80% of invasive pneumococcal disease in children younger than 6 years in the United States.^13,14 They also accounted for 74% of penicillin-susceptible S pneumoniae and 100% of pneumococci with high-level penicillin resistance isolated from children younger than age 6 years with invasive disease during a 1993-1994 surveillance by the Centers for Disease Control and Prevention (CDC).¹³

Mechanism of Action and Recommended Immunization Schedule

The conjugate vaccine is converted to a T-cell–dependent antigen, antibody formation is enhanced, and memory B cells are primed.¹⁴

The recommended immunization schedule was established as 3 primary doses at ages 2, 4, and 6 months and a booster dose at 12 to 15 months.¹ It is the first multivalent pneumococcal vaccine approved for use in children younger than 24 months.

An 89% reduction in invasive pneumococcal disease was observed in children receiving 1 or more doses, and the vaccine appears to reduce nasopharyngeal carriage of vaccine serotypes.^15,16

The older 23-valent polysaccharide vaccine does not stimulate good response in children younger than 2 years of age¹⁴ and does not reduce mucosal carriage or limit the spread of resistant strains.¹⁵

PCV-7 Supply Since 2000

In August 2001, a serious shortage of the vaccine developed in 34 state immunization programs.¹⁷ The following month, the CDC advised physicians to administer it only to children younger than 12 months and to those aged 1 to 5 years at increased risk of pneumococcal disease.¹⁸ As demand continued despite the change in recommendations, the CDC further changed recommendations to conserve vaccine supply, first suspending the fourth dose temporarily in healthy children¹⁹ and then discontinuing both the third and fourth doses.¹¹ In July 2004, production problems seemed to have resolved; the CDC recommended that every child receive 3 doses. In September, supplies were adequate for return to the 4-dose schedule.¹² As of June 2004, 67.7% of children aged 24 months had received 3 or more doses of PCV-7.²⁰ Thus, the effects of PCV-7 on the changing microbiology of AOM may only now, at the end of 2005, be fully realized.

Herd Immunity and Reduction in Carriage

Despite the shortages of vaccine during the first years of use, evidence of herd immunity and a decrease in antibiotic resistance in pneumococcal pathogens has been reported throughout the United States.^21,22 A 29% decrease in the rate of pneumococcal disease in both young children and adults has also been observed, along with a 35% reduction in the rate of disease caused by nonpenicillin-susceptible pneumococcal strains.²¹ The reduction in carriage among vaccinated children may be the reason.^21,22 Because of the impact of PCV-7, it will be important to record immunization history when collecting AOM data.

AOM treatment choices

The basis of recommendations for treating AOM depends on the presumed responsible pathogens, their susceptibility to antibiotics, and concerns for developing resistance, all influenced by clinical trial data. In practice, however, empiric choices are often made based on knowledge of local resistance patterns and of other patient characteristics; that is cost concerns, adverse event profiles, need to avoid initial treatment failure, adherence issues (eg, taste or palatability), convenience, and duration of dosing regimen.

All current guidelines recommend oral amoxicillin as first-line therapy in documented or presumed bacterial AOM. The 2004 American Academy of Pediatrics/American Academy of Family Physicians’ (AAP/AAFP) guidelines⁴ recommended increasing the dosage used for empiric treatment from 40 to 45 mg/kg/day to 80 to 90 mg/kg/day for all children. This was a result of concerns about the prevalence of penicillin-resistant S pneumoniae for which standard-dose amoxicillin is inadequate.²³

The guidelines were written and published before the data from the Kentucky and New York studies were available; therefore, although the guidelines recommended that empiric treatment of bacterial AOM should target S pneumoniae, H influenzae, and M catarrhalis, the pathogen shift discussed previously might today produce a modified antibiotic selection paradigm. The pathogen mix in persistent or recurrent AOM has already led to a guideline recommendation for high-dose amoxicillin/clavulanate, 90/6.4 mg/kg/day, cefdinir, cefprozil, cefpodoxime, cefuroxime, or ceftriaxone in these patients.²³

If an increase in the proportion of β-lactamase–producing pathogens due to PCV-7 occurs, amoxicillin may no longer be the best first choice.

Selecting Among Recommended Antibiotic Choices

As antibiotic preparations for treating bacterial AOM are oral suspensions, taste is a major factor for pediatric patients. TABLE 4 summarizes comparative taste ratings for antibiotic suspensions based on several studies and shows the range, from those that can enhance compliance to those that discourage compliance.²³

Adverse events, especially diarrhea, nausea/vomiting, and gastritis, are also of concern. These are shortcomings of amoxicillin/clavulanate, which has a higher incidence of diarrhea and nausea than cephalosporins.²⁴

Dosing frequency is also a factor among recommended agents. Amoxicillin, amoxicillin/clavulanate, cefprozil, and cefpodoxime require twice-daily dosing. Cefdinir can be effective at once-daily dosing.²⁴

Duration of approved therapy is perhaps the most critical selection factor given the reality of patient behaviors. Cefpodoxime and cefdinir are the only 2 FDA-approved agents for 5-day treatment of bacterial AOM that are also guideline-recommended.

TABLE 4

Compliance-Enhancing Ranking of Antibiotic Suspensions

Choices for Effective Initial Therapy

Considering the changing microbial population in bacterial AOM and the increasing concern of effectiveness of amoxicillin and other antibiotics against β-lactamase–producing H influenzae, the choice of therapy may need modification. Specifically, that may mean changing the choice of effective antibiotic, taking into consideration the compliance-enhancing advantages of available options.

Based on efficacy, the overall prevalence of antibiotic-resistant AOM pathogens for PCV-7-vaccinated children, the potential for adverse effects, and patient compliance issues, Block and Harrison developed an algorithm (FIGURE) for the management of AOM diagnosed by strict criteria in an otherwise healthy child between 4 months and 36 months old.²⁴ As the environment of AOM evolves, the choices for treatment must be not only effective but also the best and most appropriate.

FIGURE Antibiotic Choices for Acute Otitis Media in the 2000s